Replies to post #120239 on Biotech Values

[DewDiligence]

Were [MNTA] just saying that they were at full capacity because Sanofi might be listening?

That’s exactly right, IMO. I think NVS’ production ceiling is not based on the supply chain (as MNTA alleges), but rather on the threat of an authorized generic by SNY.